Partner Content Partner Content 3rd Annual AI-ML Drug Discovery & Development Summit Discover Case Studies of Machine Learning in Action
Partner Content Partner Content 6 Ways To Finally Drug RAS Oncogenes Are You Developing Effective Anti-RAS Therapeutics?
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.